42 Background 43 Ghana started its national programme to eliminate lymphatic filariasis (LF) in 2000, with mass 44 drug administration (MDA) with ivermectin and albendazole as main strategy. We review the 45 progress towards elimination that was made by 2016 for all endemic districts of Ghana and analyze 46 mf prevalence from sentinel and spot-check sites in endemic districts. 47 48 Methods
9 176 their children) aged ≥ 5years or with height ≥ 90cm height for those whose ages were not known, 177 including pregnant women and lactating mothers. Blood was sampled from these individuals by 178 finger pricking (middle or forth finger) and a volume of 60µl taken for thick blood smear test (2000 179 -2009) [18] . In later years (2010 -2014) , the volume of blood sampled was increased to 100µl 180 and the microfilariae were counted using a regular microscope with a rafter counting chamber [19] , 181 by trained GHS laboratory technicians. 186 TAS has a different sampling system and a different target population than a full mf survey. In 187 Ghana, the elimination programme used a district as an implementation unit (IU) for MDA. The 188 evaluation unit (EU) to assess progress of programme may also be a district or a cluster of districts 189 with a population not more than 2 million. In some of the cities where the district population was 190 more than 2 million, the district was divided into different EUs. An EU qualified to be assessed 191 after achieving treatment coverage of ≥65% for 5 years and also recording mf prevalence of <1%.
192 Those EUs who met the criteria were selected for the TAS. The TAS involved sampling of children 193 6 -7 years in primary schools within the EU after written consent from their parents. The schools 194 to be surveyed, the number of children to be tested and the critical cut-off point (maximum number 195 of positives to fail TAS) were estimated using a survey sample builder software recommended by 196 WHO [21] . A volume of 100 µl blood was taken from the children by finger pricking and test done 197 using immunochromatographic card test (ICT) [22] . The EUs where the number of positive 198 children was less than the critical cut-off point, passed the TAS (TAS-1) and the MDA was stopped 222 separately, and we only know the overall mf prevalence -aggregated over the surveyed 223 communities. These aggregated data points were included in combined trends (averages) for all 224 communities, but were not matched to community specific data for analysis for time trend analysis. 225 There were no mf surveys carried out in 2006. Mf prevalence data in 2008 and 2010 were excluded 226 from trends and analysis since communities sampled in these years were not randomly selected 227 (mf data from individuals closely related to school children who were positive using ICT during 228 school surveys). The study obtained oral informed consent from 234 adult participants while parents and guardians orally consented for their children and wards to be 235 part of this study. Due to the programmatic nature of the study with regular MDA and mf surveys 236 done in many sites, participants in these communities were aware of the program. Given that the 237 communities were mainly rural with study participants having minimal or no education and being 238 suspicious of signing documents they did not well understand, oral consent was applied and noted Table 1 ).
248 All communities in each district were expected to be treated in the same year MDA started, thus 249 geographical coverage within a district was expected to be 100%. Table S2 for more 263 details. B) Frequency distribution of the number of treatments provided by district through 2016, presented 264 separately for districts that had stopped MDA by 2016 and those with still ongoing MDA. Table S2 , supplementary data for details). The average number of treatment 271 rounds in districts that stopped MDA was 11 rounds, varying from 8 -14. In 6 communities that 272 were re-surveyed in 2014 for mf prevalence after stopping MDA in 2010, mf prevalence was 273 always below <1%. TAS-2 was performed in 69 districts in 2012 or 2015, and all districts passed.
274 Details of the TAS surveillance in Ghana are given in Table S2 , supplementary data. Figure 3A) . Overall, the total number of individuals 291 sampled per year ranged between 1,784 -19,268 (Table 1) . supplementary Table S1 ).
299 Trends in mf prevalence over time (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) 300 Community-level mf prevalence data are presented by calendar year ( Figure 3A ). The impact of 301 MDA on mf prevalence cannot clearly be seen from this figure, due to the differences between 302 communities in start year of MDA. In Figure 3B , therefore, the same data are presented by time 303 since first treatment, while Figure 3C presents these data in boxplots to better visualize the 304 distribution of the observed community-level mf prevalence. From these data, we conclude that 305 the variation in baseline prevalence was huge. The mean and median mf prevalence in surveyed 306 communities declined strongly with increasing duration of MDA. The small increase in median 307 prevalence observed 1 year after the onset of sampling is a selection effect and does not indicate a 308 lack of impact, because surveys were only done in districts with a relatively high baseline mf 309 prevalence. Although 6-7 years after the onset of MDA the median prevalence had fallen below 310 1%, there was still huge variation between communities and many communities still had mf 311 prevalence levels above 5%. The number of districts and communities surveyed declines over time, 312 because districts that have stopped MDA are no longer included in surveys. In addition, surveys 313 were selectively performed in communities in districts with low reported coverage or relatively 314 high prevalence in previous surveys. For these reasons, trends in mean and median mf prevalence 315 of surveyed villages during later stages of the control are difficult to interpret. Yet, we still see a 316 continued decline in the maximum observed prevalence levels with increasing duration of MDA.
317 In most communities with multiple measurement the mf prevalence steadily decreased over time, 318 but 12 out of 78 (15%) communities had at least once an increase between 2 time points ( Figure  378 available, especially in districts with relatively low baseline prevalence, where elimination was 379 relatively rapidly achieved, obviating the need for further surveys. In districts with relatively high 380 baseline mf prevalence, sometimes many rounds of MDA were needed to ensure that mf 381 prevalence reach below 1%. We could not assess this in the current study, as most districts are usually not resurveyed shortly 419 after stopping MDA. We have data for only 6 communities surveyed after stopping MDA, and all 420 showed mf prevalence <1%.
421 Our data had some limitations. Firstly, we only considered mf data, as antigenaemia prevalence 422 data were not always collected. Survey sites (apart from spot-check sites) were not randomly 20 423 chosen, but rather based on previous results and location, and most mf sites have been surveyed 424 only once. The low number of persons sampled combined with less sensitive mf tests in early years 425 makes the mf prevalence observed in early years less reliable (wide 95% CI, data for baseline 426 shown in supplementary data, Table S1 ). Also, the selection of participants for night blood 427 collection in each community was also not random since some households were more likely to 428 attend than others. This is particularly problematic if those not participating in surveys are also 429 more likely not to participate in MDA, resulting in biased and possibly flattered mf prevalence 430 estimates. 
